TMAM
ATRA icon

Tokio Marine Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Tokio Marine Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,080
Closed -$555K – 394
2017
Q1 		$555K Buy
+1,080
New +$447K 0.07% 216

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Tokio Marine Asset Management's ATRA Position: Q2 2017 in Review

Tokio Marine Asset Management sold out of Atara Biotherapeutics (ATRA) in Q2 2017, closing a stake of 1,080 shares — an estimated $555K sold.

Tokio Marine Asset Management first reported a position in ATRA in Q1 2017 and held it in 1 quarter. The position peaked at $555K in Q1 2017. 84 funds tracked by Wall St. Rank hold ATRA as of Q2 2017.

  • Tokio Marine Asset Management reported no remaining Atara Biotherapeutics position as of Q2 2017 after selling out during the quarter.
  • Tokio Marine Asset Management sold 1,080 Atara Biotherapeutics shares in Q2 2017, an estimated $555K.
  • Tokio Marine Asset Management first reported a position in Atara Biotherapeutics in Q1 2017 and held it in 1 quarter.
  • Tokio Marine Asset Management's Atara Biotherapeutics position peaked at $555K in Q1 2017.
  • 84 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2017.

Based on Tokio Marine Asset Management's 13F filing for Q2 2017, filed 27 Jul 2017.